title: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
abstract: BACKGROUND
  HER-2/neu, which encodes a receptor tyrosine kinase, is amplified and overexpressed in 20%-25% of human breast cancers. Such tumors are often resistant to hormone therapy. Despite a general inverse association between HER-2/neu amplification/overexpression and estrogen receptor (ER) and/or progesterone receptor (PR) expression, a fraction of patients are both HER-2/neu- and hormone receptor (HR)-positive. The efficacy of hormone therapy in this group is currently a matter of debate. To better understand the relationship between HER-2/neu positivity and HR expression, we analyzed HER-2/neu, ER, and PR as continuous variables in breast cancer cell lines and two cohorts of primary breast cancer patients.
  
  
  METHODS
  HER-2/neu and ER/PR expression was analyzed by enzyme-linked immunosorbent assay (ELISA) and enzyme immunoassay (EIA), respectively, in 14 human breast cancer cell lines, some of which had been transfected with the HER-2/neu gene. For the clinical study population, HER-2/neu protein levels were assessed by ELISA (cohort A, n = 665), and HER-2/neu gene copy number was determined using fluorescence in situ hybridization (cohort B, n = 894). ER/PR expression was analyzed by EIA (cohort A) or radioligand binding (cohort B). Associations between HER-2/neu and ER/PR expression were analyzed using Spearman's rho correlation and the chi-square test, and absolute levels were compared using the Mann-Whitney U test. All statistical tests were two-sided.
  
  
  RESULTS
  HR-positive human breast cancer cell lines transfected with the HER-2/neu gene expressed statistically significantly lower levels of ER and PR than parental lines. In the clinical cohorts, levels of HER-2/neu overexpression and gene amplification were inversely correlated with ER/PR levels (Cohort A [n = 112]: for ER, r = -0.34, P<.001; for PR, r = -0.24, P =.010. Cohort B [n = 188]: for ER, r = -0.39, P<.001; for PR, r = -0.26, P<.001). Among patients with HR-positive tumors, HER-2/neu-positive tumors had statistically significantly lower ER/PR levels than HER-2/neu-negative ones (Cohort A: for ER, median = 25 fmol/mg [interquartile range [IQR] = 13-78] versus median = 38.5 fmol/mg [IQR = 17-99] and P =.031; for PR, median = 35 fmol/mg [IQR = 12-119] versus median = 88.5 fmol/mg [IQR = 22-236] and P<.001. Cohort B: for ER, median = 44 fmol/mg [IQR = 13-156] versus median = 92 fmol/mg [IQR = 35-235] and P<.001; for PR, median = 36 fmol/mg [IQR = 13-108] versus median = 84 fmol/mg [IQR = 24-250] and P<.001). Patients with higher levels of HER-2/neu overexpression or amplification had statistically significantly lower levels of ER/PR than patients with lower levels of HER-2/neu overexpression or amplification.
  
  
  CONCLUSIONS
  Because absolute HR levels are strongly related to response to hormone therapy in primary and advanced breast cancer, reduced ER/PR expression may be one mechanism to explain the relative resistance of HER-2/neu-positive:HR-positive tumors to hormone therapy.
authors.affiliation: Division of Hematology-Oncology, Department of Medicine, and Jonsson Comprehensive Cancer Center, University of California at Los Angeles School of Medicine, Los Angeles 90095-1678, USA.
authors.forename: Gottfried
authors.initials: G
authors.lastname: Konecny
authors.forename: Giovanni
authors.initials: G
authors.lastname: Pauletti
authors.forename: Mark
authors.initials: M
authors.lastname: Pegram
authors.forename: Michael
authors.initials: M
authors.lastname: Untch
authors.forename: Sugandha
authors.initials: S
authors.lastname: Dandekar
authors.forename: Zuleima
authors.initials: Z
authors.lastname: Aguilar
authors.forename: Cindy
authors.initials: C
authors.lastname: Wilson
authors.forename: Hong-Mei
authors.initials: HM
authors.lastname: Rong
authors.forename: Ingo
authors.initials: I
authors.lastname: Bauerfeind
authors.forename: Margret
authors.initials: M
authors.lastname: Felber
authors.forename: He-Jing
authors.initials: HJ
authors.lastname: Wang
authors.forename: Malgorzata
authors.initials: M
authors.lastname: Beryt
authors.forename: Ram
authors.initials: R
authors.lastname: Seshadri
authors.forename: Herrmann
authors.initials: H
authors.lastname: Hepp
authors.forename: Dennis J
authors.initials: DJ
authors.lastname: Slamon
mesh_terms: D001943:Breast Neoplasms / Q000737:chemistry* / Q000473:pathology; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D018734:Genes, erbB-2 / Q000235:genetics*; D006801:Humans; D007124:Immunoenzyme Techniques; D017404:In Situ Hybridization, Fluorescence; D008875:Middle Aged; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D014162:Transfection; D014407:Tumor Cells, Cultured; D015854:Up-Regulation
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone